UBS analyst Eliana Merle initiated coverage of Ascendis Pharma (ASND) with a Buy rating and $196 price target UBS thinks the next 1-3 years could be “transformative” for Ascendis shares with multiple launches and a likely turn to profitability, the analyst tells investors in a research note. The firm sees growth ahead from the Yorvipath launch and the potential for upside surprises, and feels the central nervous system opportunity is underappreciated long-term.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Updates Articles for Financial Flexibility
- Ascendis Pharma price target raised to $220 from $205 at Evercore ISI
- Ascendis Pharma announces commercial availability of YORVIPATH in U.S.
- Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk
- Ascendis Pharma announces results from New InsiGHTS tril of TransCon hGH
Questions or Comments about the article? Write to editor@tipranks.com